Literature DB >> 25544507

A novel GBE1 mutation and features of polyglucosan bodies autophagy in adult polyglucosan body disease.

Simone Sampaolo1, Teresa Esposito2, Fernando Gianfrancesco3, Filomena Napolitano3, Luca Lombardi1, Roberta Lucà4, Franco Roperto4, Giuseppe Di Iorio1.   

Abstract

We report the clinical, neuro-imaging, pathological and biochemical features of an Italian family in which two siblings have the Adult Polyglucosan Body Disease (APBD). APBD is a rare autosomal recessive disorder characterized by a gradually progressive involvement of both the central and peripheral nervous systems caused by the deficiency of the glycogen branching enzyme (GBE1). The two affected siblings, a 64-year-old man and his 67-year-old sister who had complained of urinary urgency and sporadic incontinence and also progressive gait difficulty for 6 and 7 years respectively, had severely impaired deep sensations on direct examination and a moderately severe symmetrical, axonal sensory-motor neuropathy on electrophysiological testing. GBE1 activity was below 25% of the normal rate in leukocytes and sural nerves. The siblings were homozygous for the novel GBE1 mutation p.N541D. All other members of the pedigree are heterozygous and manifest no symptoms, even in the very elderly. The affected siblings showed polyglucosan bodies (PBs) included within non-myelinating Schwann cells and within lymphocyte vesicles, which were positive for the autophagy markers P62 and LC3-II at immunofluorescence microscopy.
Copyright © 2014 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Adult Polyglucosan Body Disease (APBD); Autophagy; GBE1 mutation analysis; Glycogen branching enzyme (GBE1); Polyglucosan Bodies in lymphocytes

Mesh:

Substances:

Year:  2014        PMID: 25544507     DOI: 10.1016/j.nmd.2014.11.006

Source DB:  PubMed          Journal:  Neuromuscul Disord        ISSN: 0960-8966            Impact factor:   4.296


  3 in total

1.  Adult polyglucosan body disease-an atypical compound heterozygous with a novel GBE1 mutation.

Authors:  Andreia Carvalho; Joana Nunes; Ricardo Taipa; Manuel Melo Pires; Jorge Pinto Basto; Pedro Barros
Journal:  Neurol Sci       Date:  2021-01-31       Impact factor: 3.307

2.  Definition of transcriptome-based indices for quantitative characterization of chemically disturbed stem cell development: introduction of the STOP-Toxukn and STOP-Toxukk tests.

Authors:  Vaibhav Shinde; Lisa Hoelting; Sureshkumar Perumal Srinivasan; Johannes Meisig; Kesavan Meganathan; Smita Jagtap; Marianna Grinberg; Julia Liebing; Nils Bluethgen; Jörg Rahnenführer; Eugen Rempel; Regina Stoeber; Stefan Schildknecht; Sunniva Förster; Patricio Godoy; Christoph van Thriel; John Antonydas Gaspar; Jürgen Hescheler; Tanja Waldmann; Jan G Hengstler; Marcel Leist; Agapios Sachinidis
Journal:  Arch Toxicol       Date:  2016-05-17       Impact factor: 5.153

3.  Analysis of GBE1 mutations via protein expression studies in glycogen storage disease type IV: A report on a non-progressive form with a literature review.

Authors:  Hiroyuki Iijima; Reiko Iwano; Yukichi Tanaka; Koji Muroya; Tokiko Fukuda; Hideo Sugie; Kenji Kurosawa; Masanori Adachi
Journal:  Mol Genet Metab Rep       Date:  2018-09-13
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.